HomeresearchLDN is probably one of the very few curative approaches for LONGCOVID...

LDN is probably one of the very few curative approaches for LONGCOVID and ME/CFS

-

We have been using LDN in our practice since 2011, at that time primarily for cancer patients and for multiple sclerosis. It is effective for every form of autoimmune disease by modulating the immune system toward “optimization” because it increases enkephalin/endorphin levels.

With ME/CFS patients, you have to start with ultra-low doses

We usually start with 0.1 mg – always in the morning, because ME/CFS patients somehow go berserk after 9 p.m. with the usual evening dose. Then we increase it until the first side effects occur, then reduce the dosage slightly.

Anyone without a doctor can get instructions and a prescription from me (Revers must be signed). Since most ME/CFS patients are immobile, it’s sufficient for a relative to show up with the patient’s findings and the signed revers.

I’m fully booked for many months, but it’s always sufficient to quickly write a prescription if I don’t have to answer any other questions.

 

Now, a new study has been published in May 2025 that demonstrates the mechanism of action and confirms the effect. Here is a simplified summary of the scientific article on low-dose naltrexone (LDN) and its effect on long COVID:

LDN may help with long COVID: New hope from a small dose of an old drug
Low-dose naltrexone restores TRPM3 ion channel function in natural killer cells from long COVID patients | Etianne Martini Sasso et al. | Frontiersin. Mol. Biosci., May 19, 2025, Volume 12 – 2025 | https://doi.org/10.3389/fmolb.2025.1582967

Content of the new study on the mechanism of action of LDN in ME/CFS - Long COVID

What is Long COVID?

Many people continue to suffer from symptoms long after a coronavirus infection – even if the acute illness was mild. This phenomenon is called Long COVID. Common symptoms include:

  • Fatigue
  • Difficulty concentrating (“Brain Fog”)
  • Pain
  • Sleep disorders
  • Cardiovascular and gastrointestinal complaints

These symptoms often severely impair quality of life.

What was studied?

A research team in Australia investigated whether an old drug called naltrexone, in very low doses (low-dose naltrexone, or LDN for short), could help with long COVID.

The researchers focused on a specific “ion channel” in immune cells (so-called TRPM3 channels in “natural killer cells”). These channels regulate how calcium enters the cell—a crucial process for the proper functioning of cells. In long COVID patients, these channels are disrupted, weakening the immune system and possibly contributing to the symptoms.

What is LDN?

Naltrexone is a drug normally used in high doses to treat alcohol or opiate addiction. However, at very low doses (approximately 3–5 mg daily), it has a completely different effect:

  • It has anti-inflammatory properties
  • It positively influences the immune system
  • It could restore impaired cell functions

How did the study proceed?

The scientists examined three groups of people:

  • Healthy controls
  • Long COVID patients without treatment
  • Long COVID patients taking LDN

Immune cells from the blood of all of them were examined, particularly the activity of the TRPM3 channels.

What was the result?

  • In Long COVID patients without LDN, the TRPM3 channels were significantly disrupted.
  • In patients taking LDN, these channels functioned almost as well as in healthy people.
  • LDN was able to normalize the impaired calcium uptake.

What does this mean?

LDN appears to improve the function of important immune cells in Long COVID. This is the first direct evidence that LDN can specifically restore impaired cell function in this disease.

Were there any side effects?

This study found no negative effects of LDN. It even showed a slight improvement in quality of life and a reduction in everyday restrictions among LDN users.

Why is this important?

  • Long COVID affects the worldvmillions of people.
  • There are hardly any effective treatments.
  • LDN is inexpensive, well-tolerated, and already approved – it could be used off-label.

Conclusion

This study provides promising evidence that LDN could be a safe and effective option for long COVID. It improves immune cell function and could help alleviate symptoms. Further large studies are needed, but the results offer hope for those affected.

 

It’s completely crazy to treat CFS without LDN!

I even take LDN myself – simply for optimization, “Happy live – happy live.”

 

I wrote a similar article a few months ago:

LDN is helpful for CFS fatigue syndrome

 

And don’t forget the chronic, long-term treatment of the viruses. None of that helps much – but IT HELPS!!!

Long term EBV treatment usefull for ME/CFS

 

about LDN

Back then, we were the first in Europe to bring LDN into the spotlight.

At that time, doctors in the US who worked with it were threatened with having their licenses revoked.

I’ve experienced “miracles” with it time and again. At lectures on LDN, I say, “It may sound boastful, but it feels true: Since LDN, our cancer patients no longer die.”

The difference was so clear compared to the “pre-LDN era.” Here is my first article on LDN back then.

Here is the link to the Autotranslation via Google of this first Collection of LDN-Datas from 2011

https://ganzemedizin-at.translate.goog/ldn/?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=de&_x_tr_pto=wapp

 

I’ve written about 30 articles about LDN.

The most impressive one – and I would also recommend it to colleagues – is the approximately 1.5-hour interview with one of the first users, Dr. Bihari – then Minister of Health in New York, who successfully treated hundreds of cancer, AIDS, and MS patients with it. I’ve included the video in the following article. linked in

here the Google english translation of my website back then, the important video of Dr. Bihari is anyways in English

https://ganzemedizin-at.translate.goog/low-dose-naltrexone-historische-hintergrund-infos/?_x_tr_sl=de&_x_tr_tl=en&_x_tr_hl=de&_x_tr_pto=wapp

 

 

 

 

Google CENSORSHIP!

Google censors my homepage quite a bit, sometimes I am not even able to find my articles on Google. So please sign up for the newsletter and share it with friends or via Facebook and use the search function on my website. Follow me on Twitter, where I also announce important articles.